Two Doses of Dexmedetomidine as Adjuvent to Bupivacaine in Tap Block

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-01-31

Study Completion Date

2026-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study to determine the optimal dose of dexmedetomidine as an adjuvant to bupivacaine in U.S guided TAP block for preemptive analgesia In patients undergoing lower abdominal cancer surgeries.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Dexmedetomidine as an Adjuvant to Bupivacaine for Ultrasound-Guided External Oblique Intercostal Block

NCT07263165

Opioid Consumption, Postoperative

NOT_YET_RECRUITING NA

Pharmacokinetics and Dynamics of Dexmedetomidine as Adjuvant in TAP Block

NCT03328299

Postoperative Pain

COMPLETED PHASE2/PHASE3

Effect of Intravenous or Intrathecal Dexmedetomidine on Bupivacaine Spinal Block in Lower Abdominal Surgery

NCT06654531

Spinal Anesthetics Causing Adverse Effects in Therapeutic Use

COMPLETED PHASE2/PHASE3

Dexmedetomine vs Dexamethasone in TAB Block for Abdominal Surgries

NCT05323565

Anesthesia

UNKNOWN PHASE4

Dexmedetomidine Versus Fentanyl Added to Levobupivacaine for Transversus Abdominis Plane (TAP) Block

NCT03778671

Transversus Abdominis Block

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The transversus abdominis plane (TAP) involves innervations of the anterolateral abdominal wall derived from T6-L1. The block can be given either by anatomical landmark technique or by using an ultrasound probe. The local anesthetic is deposited in a plane between internal oblique and transversus abdominis muscle. It provides adequate postoperative analgesia following various abdominal surgeries.Dexmedetomidine is an alpha-2 agonist that has been approved as a venous sedative and an adjuvant for pain relief .In previous studies, the addition of dexmedetomidine to bupivacaine in the TAP block has prolonged the effect of this block . So far, the optimal dose of dexmedetomidine for the TAP block has not been determined.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Post Operative Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Patients will receive pre-emptive ultrasound-guided tap block with two different doses of dexmedetomidine in 20 ml volume added to 20 mL of 0.25% bupivacaine (40 ml in total) 20 ml will be applied on each side of the abdominal wall after induction of GA.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

tap block with 0.5 μg/kg dexmedetomidine

will receive pre-emptive ultrasound-guided tap block with 0.5 μg/kg dexmedetomidine in 20 ml volume added to 20 mL of 0.25% bupivacaine (40 ml in total) 20 ml will be applied on each side of the abdominal wall after induction of GA.

Group Type ACTIVE_COMPARATOR

Dexmedetomidine as adjuvent to bupvacaine in tap block

Intervention Type DRUG

The analgesic effect of Two different doses of dexmedetomidine as adjuvent to bupivacaine in tap block

tap block with 1.5 μg/kg dexmedetomidine

will receive pre-emptive ultrasound-guided tap block with 1.5 μg/kg dexmedetomidine in 20 ml volume added to 20 mL of 0.25% bupivacaine (40 ml in total) 20 ml will be applied on each side of the abdominal wall after induction of GA.

Group Type ACTIVE_COMPARATOR

Dexmedetomidine as adjuvent to bupvacaine in tap block

Intervention Type DRUG

The analgesic effect of Two different doses of dexmedetomidine as adjuvent to bupivacaine in tap block

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dexmedetomidine as adjuvent to bupvacaine in tap block

The analgesic effect of Two different doses of dexmedetomidine as adjuvent to bupivacaine in tap block

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Precedex

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age from 18 to 65 years old
* lower abdominal cancer surgery

Exclusion Criteria

* patient refusal
* the local anesthetic allergy
* coagulopathy
* local infection at the procedure site
* psychic patients
* patient on chronic opioid use

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No